上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会的 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2023 年第五次临时股东大会（以 下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简 称"《公司法》"）、《上市公司股东大会规则》等法律、法规和其他规范性文件以 及《上海睿昂基因科技股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2023-078 上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 9 月 13 日 （二） 股东大会召开的地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 3 | | --- | --- | | 普通股股东人数 | 3 | | 2、出席会议的股东所持有的表决权数量 | 17,101,120 | | 普通股股东所持有表决权数量 | 17,101,120 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 30.6165 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 30.6165 ...

2023 年 9 月 上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会会议资料 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会 会议资料 上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会会议资料 | | | | 2023 年第五次临时股东大会会议须知 3 | | | --- | --- | | 年第五次临时股东大会会议议程 5 2023 | | | 2023 年第五次临时股东大会会议议案 7 | | | 议案一《关于公司前次募集资金使用情况报告的议案》 7 | | | 议案二《关于公司内部控制自我评价报告的议案》 8 | | | 议案三《关于公司内部控制鉴证报告的议案》 9 | | | 议案四《关于公司最近三年及一期非经常性损益明细的议案》 10 | | | 议案五《关于延长公司向不特定对象发行可转换公司债券相关决议有效期及股 | | | 东大会授权董事会全权办理本次相关事宜有效期的议案》 | 11 | 上海睿昂基因科技股份有限公司 2023 年第五次临时股东大会会议资料 上海睿昂基因科技股份有限公司 2023 年第五次临时股东 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, achieving a total of 500 million RMB, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2023 was approximately ¥127.57 million, a decrease of 26.14% compared to ¥172.71 million in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2023 was approximately ¥16.24 million, down 23.72% from ¥21.28 million in the previous year[24]. - The basic earnings per share for the first half of 2023 was ¥0.29, a decline of 23.68% compared to ¥0.38 in the same period last year[22]. - The net profit after deducting non-recurring gains and losses for the first half of 2023 was approximately ¥15.28 million, down 17.33% from ¥18.49 million in the previous year[24]. - The company achieved revenue of CNY 127.57 million in the first half of 2023, a year-on-year decrease of 26.14%, primarily due to a significant drop in COVID-related revenue, which was CNY 0.93 million, down 98.51% compared to the previous year[78]. - Non-COVID-related business revenue increased by 14.57% year-on-year, totaling CNY 126.64 million, with a gross margin of 72.29%, up 11.82 percentage points from the previous year[79]. - The company reported a net cash flow from operating activities significantly increased to approximately ¥23.81 million, up 3,345.79% from ¥0.69 million in the previous year[24]. Market Expansion and Product Development - User data indicates that the active user base has expanded to 1.2 million, marking a 30% increase compared to the previous year[1]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 25%[1]. - New product launches are expected to contribute an additional 100 million RMB in revenue by the end of the year[1]. - Market expansion efforts include entering three new provinces, which are anticipated to increase market share by 15%[1]. - The company is exploring potential acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by Q4 2023[1]. - A new strategic partnership has been established with a leading healthcare provider, expected to drive additional revenue of 80 million RMB over the next year[1]. - The company is currently in the market expansion and product development phase, with ongoing uncertainties regarding the performance of newly acquired subsidiaries[106]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 50 million RMB for new technology development in the diagnostics sector[1]. - The company's R&D expenditure accounted for 24.56% of operating revenue, an increase of 6.92 percentage points from 17.64% in the previous year[22]. - The total R&D investment for the period reached ¥31,327,640.79, an increase of 2.81% compared to ¥30,470,573.27 in the same period last year[63]. - The company has developed proprietary ctDNA enrichment and noise reduction technologies, enhancing the sensitivity and accuracy of its digital PCR products[44]. - The company has established a strong R&D team with expertise in advanced technologies such as S-ddPCR and microfluidic integrated detection platforms[71]. - The company has developed 3 core front-end technologies, 6 advanced molecular diagnostic application technologies, and 2 forward-looking reserve technologies in the field of molecular diagnostics[58]. Product Portfolio and Market Position - The company focuses on precision medical testing in oncology, aiming to become the most trusted gene company in the field[28]. - The main products include molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious diseases, with a strong emphasis on blood cancer diagnostics[30]. - The company has launched 108 diagnostic reagent kits, with several being the first or only products in the domestic market, indicating a leading market position[32]. - The company holds over 66% market share in the leukemia fusion gene detection market with its three fusion gene reagent kits, which have been the only products in the market for 6 years[38]. - The lymphoma gene rearrangement product, launched in September 2020, is the only product in the domestic lymphoma field, achieving a detection accuracy rate of 99.12% and reducing the diagnosis cycle to 8 days[41]. - The company’s digital PCR platform has shown a detection rate approximately double that of competitors in the liquid biopsy field, with the T790M kit expected to receive Class III medical device certification by the end of 2023[45]. Financial Risks and Challenges - The company has identified key risks, including regulatory changes and market competition, which could impact future performance[1]. - The company faces risks in new product development due to the long cycles and high costs associated with technology-driven industries, which may lead to potential failures if not managed properly[97]. - The company is at risk of losing competitive advantage if core technologies are leaked or if there is a significant turnover of key technical personnel, which could hinder ongoing projects[100][101]. - The company faces risks related to product quality and market competition, which could adversely affect profitability if not managed effectively[104][7]. Corporate Governance and Shareholder Relations - The company has appointed new senior management, including two vice general managers, to enhance operational efficiency[138]. - The company held four shareholder meetings in 2023, all resolutions were passed without any rejections[136]. - The company has no plans for profit distribution or capital reserve transfer for the half-year period, with no dividends or stock bonuses proposed[140]. - The company has approved the grant of 26,000 restricted stocks to incentive targets as part of its stock incentive plan[141]. - The controlling shareholder, Xiong Hui, intends to hold shares of Ruian Gene long-term to maintain control and share in the company's operational results[160]. Environmental Responsibility - The company invested 544,700 RMB in environmental protection during the reporting period[144]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[145]. - The company ensures that its wastewater meets the standards set by the municipal sewage treatment facilities, with no pollutants exceeding limits[145]. - The company has established hazardous waste storage areas in each production workshop for proper handling of hazardous waste[146]. - The company did not implement any carbon reduction measures during the reporting period[147]. Strategic Partnerships and Collaborations - The collaboration between Sichuan University West China Hospital and Ruian Gene on the study of "MRD detection in DLBCL using IgH/IgK gene rearrangement NGS" has resulted in a case report published on June 28, 2023[86]. - Ruian Gene and Beijing University Chongqing Big Data Research Institute established a "Gene Intelligent Big Data Joint Laboratory" focusing on blood system, solid tumors, and elderly diseases, aiming to enhance precision medicine through AI algorithms[87]. - On March 21, 2023, Ruian Gene signed a strategic cooperation agreement with Guoyao Shengkang, leveraging a marketing network covering over 20,000 medical institutions and 40,000 clinical doctors to enhance product reach[88].

www.zhcpa.cn 关于上海睿昂基因科技股份有限公司 最近三年一期非经常性损益的鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5~8, 12 and 23, Block A, UDC Times Building. No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 目 录 | | 页 次 | | --- | --- | | 一、最近三年一期非经常性损益的鉴证报告 | 1-3 | | 二、最近三年一期非经常性损益明细表 | 4-5 | | 三、最近三年一期非经常性损益明细表附注 | 6-9 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 ww ...

上海睿昂基因科技股份有限公司 前次募集资金使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 目 景 | | 页 次 | | --- | --- | | 一、前次募集资金使用情况鉴证报告 | 1-3 | | 二、上海睿昂基因科技股份有限公司关于前次募集资金 | | | 使用情况的报告 | 4-10 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5~8, 12 and 23, Block A, UDC Times Building. No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 前次募集资 ...

上海睿昂基因科技股份有限公司 内部控制自我评价报告 (一) 评价程序：成立评价小组，制定评价方案；现场检查；评价小组研究 认定内部控制缺陷；整改方案进行讨论和审核；按照规定权限和程序报董事会审 议批准。 (二) 评价方法：组成评价小组综合运用个别访谈、调查问卷、专题讨论、 穿行测试、统计抽样、比较分析等多种方法，广泛收集本公司内部控制设计和有 效运行的证据，研究认定内部控制设计缺陷和运行缺陷。 三、内部控制评价范围 上海睿昂基因科技股份有限公司全体股东： 根据财政部、证监会等部门联合发布的《企业内部控制基本规范》及其配套 指引的规定和其他内部控制监管要求(以下简称企业内部控制体系)，结合本公司 (以下简称公司)内部控制制度和评价方法，在内部控制日常监督和专项监督的基 础上，我们对公司截止至2023年6月30日(内部控制评价报告基准日)的内部控建 立的合理性、完整性和实施的有效性进行了评价，并就内部控制设计和运行中存 在的缺陷进行了认定。现将公司截至2023年06月30日与公司财务报表相关的内部 控制自我评价情况报告如下： 一、重要声明 内部控制是由企业董事会、监事会、经理层和全体员工实施的、旨在实现控 制目标 ...

上海睿昂基因科技股份有限公司 内部控制鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn E 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查验 . 报告编码:浙23LWDNON1X 目 录 一、内部控制鉴证报告 二、内部控制自我评价报告 4-14 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors S−8, 12 and 23, Block A, UDC Times Building. No. 8 Xinye Road. Qianjiang New City, Hangzhou Tel. 0571-88879999 www.zhcpa.cn 页 次 1-3 内部控制鉴证报告 中汇会鉴[20 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2023-070 上海睿昂基因科技股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上 海证券交易所科创板股票上市规则》等有关法律、法规及相关文件的规定，上 海睿昂基因科技股份有限公司（以下简称"公司"或"本公司"）就2023年半年度 募集资金存放与实际使用情况的专项报告说明如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意上海睿昂基因科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2021〕1126号），同意公司首次 公开发行股票的注册申请。并经上海证券交易所同意，公司首次向社会公众公 开发行人民币普通股（A股）股票1,390.00万股，本次发行价格为每股人民币 18.42元，募集资金总额为人民币 ...

上海睿昂基因科技股份有限公司 独立董事关于第二届董事会第十八次会议相关事项 的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》（以下简称"《证券法》"）《上市公司独立董事规则》《上海证券交易所 科创板股票上市规则》等法律、法规及规范性文件以及《上海睿昂基因科技股份有 限公司章程》（以下简称"《公司章程》"）等有关规定，我们作为上海睿昂基因科 技股份有限公司（以下简称"公司"）的独立董事，对公司第二届董事会第十八次会 议审议的相关事项发表如下独立意见： 一、《关于 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》 的独立意见 我们认为：公司编制的《关于 2023 年半年度募集资金存放与实际使用情况的 专项报告》真实反映了公司 2023 年半年度募集资金存放和使用的实际情况，符合 中国证券监督管理委员会（以下简称"中国证监会"）、上海证券交易所关于上 市公司募集资金存放和使用的相关监管要求和管理办法，对募集资金进行了专户 存储和专项使用，不存在募集资金存放和使用违规的行为，不存在损害股东利益 的情形。公司所披露的募集资金存放和使用情况信息与实际情况一致，如实 ...